The IL-1 Pathway Is Hyperactive in Hidradenitis Suppurativa and Contributes to Skin Infiltration and Destruction.


Journal

The Journal of investigative dermatology
ISSN: 1523-1747
Titre abrégé: J Invest Dermatol
Pays: United States
ID NLM: 0426720

Informations de publication

Date de publication:
06 2019
Historique:
received: 02 03 2018
revised: 16 11 2018
accepted: 16 11 2018
pubmed: 12 12 2018
medline: 10 5 2020
entrez: 12 12 2018
Statut: ppublish

Résumé

Hidradenitis suppurativa (HS) (also designated acne inversa) is a chronic inflammatory disease characterized by painful purulent skin lesions and progressive destruction of skin architecture. Despite the high burden for the patients, pathogenetic pathways underlying HS alterations remain obscure. When we examined the HS cytokine pattern, IL-1β turned out to be a highly prominent cytokine, overexpressed even compared with psoriatic lesions. Analyses of IL-1β-induced transcriptome in various cell types showed overlapping profiles, with upregulations of molecules causing immune cell infiltration and extracellular matrix degradation, and of specific cytokines including IL-6, IL-32, and IL-36. Matching cellular IL-1 receptor levels, dermal fibroblasts showed both the strongest and broadest IL-1β response, which was not clearly shared or strengthened by other cytokines. The IL-1β signature was specifically present in HS lesions and could be reversed by application of IL-1 receptor antagonist. Search for blood parameters associated with IL-1β pathway activity in HS identified serum amyloid A, which was synergistically induced by IL-1β and IL-6 in hepatocytes. Consequently, strongly elevated blood serum amyloid A levels in HS correlated positively with the extent of inflammatory skin alterations. In summary, the IL-1β pathway represents a pathogenetic cascade, whose activity may be therapeutically targeted and monitored by blood SAA levels.

Identifiants

pubmed: 30528824
pii: S0022-202X(18)32909-9
doi: 10.1016/j.jid.2018.11.018
pii:
doi:

Substances chimiques

IL1B protein, human 0
IL6 protein, human 0
Interleukin 1 Receptor Antagonist Protein 0
Interleukin-1beta 0
Interleukin-6 0
Receptors, Interleukin-1 0
Serum Amyloid A Protein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1294-1305

Informations de copyright

Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Ellen Witte-Händel (E)

Interdisciplinary Group Molecular Immunopathology, Dermatology/Medical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Psoriasis Research and Treatment Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Kerstin Wolk (K)

Interdisciplinary Group Molecular Immunopathology, Dermatology/Medical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Psoriasis Research and Treatment Center, Charité-Universitätsmedizin Berlin, Berlin, Germany; Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Athanasia Tsaousi (A)

Psoriasis Research and Treatment Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Marie Luise Irmer (ML)

Psoriasis Research and Treatment Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Rotraut Mößner (R)

Department of Dermatology, University Medical Center Göttingen, Göttingen, Germany.

Orr Shomroni (O)

Transcriptome and Genome Core Unit, University Medical Center Göttungen, Göttingen, Germany.

Thomas Lingner (T)

Transcriptome and Genome Core Unit, University Medical Center Göttungen, Göttingen, Germany.

Katrin Witte (K)

Interdisciplinary Group Molecular Immunopathology, Dermatology/Medical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Desiree Kunkel (D)

Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Gabriela Salinas (G)

Transcriptome and Genome Core Unit, University Medical Center Göttungen, Göttingen, Germany.

Stefan Jodl (S)

Research and Development, Pharmaceuticals, Bayer AG, Berlin and Wuppertal, Germany.

Nicole Schmidt (N)

Research and Development, Pharmaceuticals, Bayer AG, Berlin and Wuppertal, Germany.

Wolfram Sterry (W)

Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Hans-Dieter Volk (HD)

Berlin-Brandenburg Center for Regenerative Therapies, Charité-Universitätsmedizin Berlin, Berlin, Germany; Institute of Medical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Evangelos J Giamarellos-Bourboulis (EJ)

4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.

Anna Pokrywka (A)

Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Wolf-Dietrich Döcke (WD)

Research and Development, Pharmaceuticals, Bayer AG, Berlin and Wuppertal, Germany.

Sylke Schneider-Burrus (S)

Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Robert Sabat (R)

Interdisciplinary Group Molecular Immunopathology, Dermatology/Medical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany; Psoriasis Research and Treatment Center, Charité-Universitätsmedizin Berlin, Berlin, Germany. Electronic address: robert.sabat@charite.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH